ICU MEDICAL INC/DE(ICUI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,933 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ICUI Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ICU MEDICAL INC/DE (ICUI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ICUI at 40.5/100 on a 32-signal composite quality model, placing it at rank #1,933 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (8.4) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 37.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2025), ICU MEDICAL INC/DE reports quarterly revenue of $540.7M, an operating margin of 1.0%, free cash flow of $36.0M. Top institutional holders of ICUI by reported 13-F value include BlackRock,, JANUS HENDERSON GROUP PLC, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. ICUI trades on the Nasdaq exchange and files with the SEC under CIK 883984. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ICUI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ICU MEDICAL INC/DE directly from SEC EDGAR. ICU MEDICAL INC/DE's 13F Pro composite quality score has ranged between 39 and 52 since 2021, currently 40.5 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.
Revenue
Q4 2025
$540.7M
Free Cash Flow
Q4 2025
$36.0M
Operating Margin
Q4 2025
1.0%
ROIC
Q4 2025
0.2%
D/E Ratio
Q4 2025
0.60
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-6.3% YoYNet Income
+100.6% YoYOperating Income
-0.3% YoYEPS (Diluted)
+100.6% YoYTotal Assets
-3.6% YoYTotal Debt
-18.8% YoYOp. Cash Flow
-11.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $2.23B -6.3% | $2.38B +5.4% | $2.26B -0.9% | $2.28B +79.4% | $1.27B +0.4% | $1.27B |
| Net Income | $732.0K +100.6% | $-117.7M -296.9% | $-29.7M +60.1% | $-74.3M -185.5% | $86.9M -14.0% | $101.0M |
| Operating Income | $42.8M -0.3% | $43.0M +88.2% | $22.8M +153.2% | $-42.9M -143.7% | $98.2M -8.6% | $107.4M |
| EPS (Diluted) | $0.03 +100.6% | $-4.83 -292.7% | $-1.23 +60.5% | $-3.11 -177.4% | $4.02 -14.3% | $4.69 |
| Total Assets | $4.05B -3.6% | $4.20B -4.0% | $4.38B -3.0% | $4.52B +156.0% | $1.76B +4.2% | $1.69B |
| Total Debt | $1.28B -18.8% | $1.58B -2.8% | $1.63B -1.5% | $1.65B | — | $0.00 |
| Operating Cash Flow | $179.8M -11.9% | $204.0M +22.8% | $166.2M +367.5% | $-62.1M -127.9% | $222.8M +118.6% | $101.9M |
Get alerted when ICUI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ICU MEDICAL INC/DE including:
Top Institutional Holders of ICUI
BlackRock, Inc.
$466.0M3,608,322 shJANUS HENDERSON GROUP PLC
$345.6M2,676,012 shVANGUARD PORTFOLIO MANAGEMENT LLC
$185.7M1,437,676 shFULLER & THALER ASSET MANAGEMENT, INC.
$157.6M1,220,539 shVANGUARD CAPITAL MANAGEMENT LLC
$143.6M1,111,875 shDIMENSIONAL FUND ADVISORS LP
$127.1M983,802 shSTATE STREET CORP
$125.0M968,053 shSCHRODER INVESTMENT MANAGEMENT GROUP
$87.9M701,280 shRiver Road Asset Management, LLC
$83.5M646,430 shGEODE CAPITAL MANAGEMENT, LLC
$79.0M611,219 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $466.0M | 3,608,322 |
| JANUS HENDERSON GROUP PLC | $345.6M | 2,676,012 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $185.7M | 1,437,676 |
| FULLER & THALER ASSET MANAGEMENT, INC. | $157.6M | 1,220,539 |
| VANGUARD CAPITAL MANAGEMENT LLC | $143.6M | 1,111,875 |
| DIMENSIONAL FUND ADVISORS LP | $127.1M | 983,802 |
| STATE STREET CORP | $125.0M | 968,053 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $87.9M | 701,280 |
| River Road Asset Management, LLC | $83.5M | 646,430 |
| GEODE CAPITAL MANAGEMENT, LLC | $79.0M | 611,219 |
More Healthcare Companies
View all Healthcare →Put ICUI on your watchlist
Track score changes the day ICU MEDICAL INC/DE files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ICUI a good stock to buy?
13F Pro's AI-powered analysis of ICU MEDICAL INC/DE (ICUI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ICUI are available on the ICUI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ICUI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ICUI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ICU MEDICAL INC/DE's investment landscape.